Literature DB >> 23612468

Clinical characteristics and outcome of 107 adult patients with chronic Chagas disease and parasitological cure criteria.

Graciela L Bertocchi1, Carlos A Vigliano, Bruno G Lococo, Marcos A Petti, Rodolfo J Viotti.   

Abstract

BACKGROUND: The cure in adult patients with chronic Chagas disease and the relationship between parasitological and clinical evolution is still under debate. The aim of this study was to analyze the clinical, epidemiological and progression features of the disease in a patient population who became serologically negative either spontaneously or post-etiological treatment.
METHODS: We included 107 patients over 20 years old with three different confirmed reactive anti-Trypanosoma cruzi serologic tests on admission, and a minimum of two years of follow-up. Patients were assigned to clinical groups according to Kuschnir. Change of clinical group was considered a heart disease progression criterion, and seronegative conversion of two or three as parasitological cure criterion.
RESULTS: From 107 patients with parasitological cure, 82 had received treatment (77%) and 25 became spontaneously seronegative (23%). Forty-six (43%) and 61 (57%) patients had two and three negative serological tests, respectively. No differences in clinical groups, ECG, echocardiogram and heart disease progression were found in patients who became negative spontaneously or post-treatment. The clinical progression and ECG changes were observed in 5/107 (5%) and 11/107 (10%) respectively, in a mean of 10 years follow-up.
CONCLUSIONS: Adults with chronic Chagas disease can cure, mostly post-etiological treatment, but also spontaneously, showing a favourable clinical outcome.

Entities:  

Keywords:  Benznidazole; Chagas disease; Disease progression; Parasitological cure; Spontaneous seroconversion; Treatment

Mesh:

Substances:

Year:  2013        PMID: 23612468     DOI: 10.1093/trstmh/trt029

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  20 in total

1.  A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection.

Authors:  Ana Fernández-Villegas; Elena Pérez-Antón; Inmaculada Gómez; Adriana Egui; M Carmen Thomas; Bartolomé Carrilero; Ángel Del Pozo; Maialen Ceballos; Eduardo Andrés-León; Miguel Ángel López-Ruz; Eusebio Gainza; Enrique Oquiñena; Manuel Segovia; Manuel Carlos López
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 2.  Chronic Chagas Disease-the Potential Role of Reinfections in Cardiomyopathy Pathogenesis.

Authors:  Christian Olivo Freites; Hendrik Sy; Amal Gharamti; Nelson I Agudelo Higuita; Carlos Franco-Paredes; José Antonio Suárez; Andrés F Henao-Martínez
Journal:  Curr Heart Fail Rep       Date:  2022-08-11

3.  Towards a paradigm shift in the treatment of chronic Chagas disease.

Authors:  R Viotti; B Alarcón de Noya; T Araujo-Jorge; M J Grijalva; F Guhl; M C López; J M Ramsey; I Ribeiro; A G Schijman; S Sosa-Estani; F Torrico; J Gascon
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

4.  Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).

Authors:  Maite Vallejo; Pedro Pa Reyes; Mireya Martinez Garcia; Alejandro G Gonzalez Garay
Journal:  Cochrane Database Syst Rev       Date:  2020-12-11

5.  Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia.

Authors:  Fiorella Bianchi; Zulma Cucunubá; Felipe Guhl; Nadia Lorena González; Hector Freilij; Rubén Santiago Nicholls; Juan David Ramírez; Marleny Montilla; Astrid Carolina Flórez; Fernando Rosas; Victor Saavedra; Nubia Silva
Journal:  PLoS Negl Trop Dis       Date:  2015-02-27

6.  Reaching for the Holy Grail: insights from infection/cure models on the prospects for vaccines for Trypanosoma cruzi infection.

Authors:  Juan Bustamante; Rick Tarleton
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-04-28       Impact factor: 2.743

Review 7.  Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.

Authors:  Yanina Sguassero; Cristina B Cuesta; Karen N Roberts; Elizabeth Hicks; Daniel Comandé; Agustín Ciapponi; Sergio Sosa-Estani
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

Review 8.  Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease.

Authors:  María Cecilia Albareda; Susana Adriana Laucella
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-05       Impact factor: 2.743

9.  A refined genome phage display methodology delineates the human antibody response in patients with Chagas disease.

Authors:  André Azevedo Reis Teixeira; Luis Rodriguez Carnero; Andréia Kuramoto; Fenny Hui Fen Tang; Carlos Hernique Gomes; Natalia Bueno Pereira; Léa Campos de Oliveira; Regina Garrini; Jhonatas Sirino Monteiro; João Carlos Setubal; Ester Cerdeira Sabino; Renata Pasqualini; Walter Colli; Wadih Arap; Maria Júlia Manso Alves; Edécio Cunha-Neto; Ricardo José Giordano
Journal:  iScience       Date:  2021-05-15

10.  Polyfunctional T cell responses in children in early stages of chronic Trypanosoma cruzi infection contrast with monofunctional responses of long-term infected adults.

Authors:  María C Albareda; Ana M De Rissio; Gonzalo Tomas; Alicia Serjan; María G Alvarez; Rodolfo Viotti; Laura E Fichera; Mónica I Esteva; Daniel Potente; Alejandro Armenti; Rick L Tarleton; Susana A Laucella
Journal:  PLoS Negl Trop Dis       Date:  2013-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.